Nuo Therapeutics, Inc. (AURX)
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.8000 - 0.8000 |
| 52-week range | 0.4010 - 2.4000 |
| Volume | |
| Avg. volume | 2,080 |
| Market cap | 35.393M |
| Beta (5Y monthly) | -678.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireNuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today it has been selected to exhibit the Aurix® System, the first platelet rich plasma (PRP) device indicated for chronic diabetic wounds, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven he
- GlobeNewswire
Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage (WCA), the nation’s leading wound care consulting firm has added the Aurix® System to its formulary. Founded in 2002, Wound Care Advantage (WCA) has established a large network of successful wound he
